Granted Patent B2

US 12,365,743 · App. 18/172,987 · Granted Jul 22, 2025

Inventors: John R. Desjarlais (Pasadena, CA); Gregory Moore (Azusa, CA); Michael Hedvat (Encino, CA); Juan Diaz (Anaheim Hills, CA); Veronica Gusti Zeng (Duarte, CA); Matthew Adam Dragovich (Monrovia, CA); Joseph Erhardt (Sellersville, PA); Theresa McDevitt (Warminster, PA); Fouad Moussa (Allentown, PA); Pankaj Seth (Norristown, PA); Fei Shen (Collegeville, PA); Adam Zwolak (Bala Cynwyd, PA)

Assignee: Xencor, Inc.

C07K16/468C07K16/2818C07K16/3069C07K2317/31C07K2317/565C07K2317/622

Abstract

Claims (10)

1. A heterodimeric antibody comprising:

a) a first monomer comprising:

i) a single chain variable fragment (scFv); and

ii) a first Fc domain, wherein the scFv is covalently attached to the N-terminus of the first Fc domain using a domain linker;

b) a second monomer comprising, from N-terminal to C-terminal, a VH1-CH1-hinge-CH2-CH3, wherein VH1 is a first variable heavy domain and CH2-CH3 is a second Fc domain; and

c) a light chain comprising, from N-terminal to C-terminal, VL1-CL, wherein VL1 is a first variable light domain and CL is a constant light domain,

wherein the scFv comprises a second VH domain (VH2), a scFv linker, and a second variable light domain (VL2),

wherein the VH1 and the VL1 together form a first antigen binding domain (ABD) and the VH2 and the VL2 together form a second ABD, and

wherein the first ABD binds Prostate Specific Membrane Antigen (PSMA) and the second ABD binds CD28, and

wherein the VH1 has an amino acid sequence of SEQ ID NO: 214, the VH2 has an amino acid sequence of SEQ ID NO: 396, the VL1 has an amino acid of SEQ ID NO: 218, and the VL2 has an amino acid sequence of SEQ ID NO: 400.

Assignments (3)

Continuity (2)

References Cited (238)